ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Atrasentan

Also written as “Drug: Atrasentan”, “atrasentan” and “0.25 mg Atrasentan QD”.

Its studies are mostly in Glomerulonephritis, IGA · Prostatic Neoplasms · Renal Insufficiency, Chronic · Kidney Diseases · Diabetic Nephropathies, led by 3 companies.

Drug pageAtrasentan: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 10, 200215 company-led studies, 4 open or runningNext primary completion: Apr 14, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbottits history only50 open or runningphase 3since May 10, 2002May 10, 2002none ahead
AbbVie50 open or runningphase 3since May 17, 2013Jun 11, 2009none ahead
Novartisits history only54 open or runningphase 3since Sep 12, 2020Sep 12, 2020Apr 14, 2028phase 3 · NCT04573478

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 11, 2009First study: phase 2 study in Renal Insufficiency, ChronicFirst studyNCT00920764 · 92 enrolled · United States, Puerto Rico
  2. Apr 19, 2011Phase 2 study in Renal Insufficiency, ChronicNCT01356849 · 149 enrolled · United States, Canada, Puerto Rico and more
  3. Jul 20, 2011Phase 2 study in Renal Insufficiency, ChronicNCT01399580 · 48 enrolled · United States
  4. May 17, 2013Phase 3 study in Diabetic NephropathiesNCT01858532 · 5,107 enrolled
  5. Apr 14, 2014Phase 2 study in Kidney DiseasesNCT02118714 · 20 enrolled · United States, Germany, Italy and more

TargetBeta

EDNRA →read by rule
“Endothelin receptor ET-A antagonist”ChEMBL 37, by rule

Other programs on EDNRA

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437
sparsentanruletravere-therapeutics-incphase 49
zibotentanAstraZenecaphase 323
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

All 5 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02118714Kidney Diseases · United States, Germany, Italy and more2CompletedApr 18, 201820
NCT01858532Diabetic Nephropathies3TerminatedMar 29, 20185,107
NCT01399580Renal Insufficiency, Chronic · United States2CompletedSep 201248
NCT01356849Renal Insufficiency, Chronic · United States, Canada, Puerto Rico and more2CompletedAug 2012149
NCT00920764Renal Insufficiency, Chronic · United States, Puerto Rico2CompletedApr 201092

How it is read

Names in the registry

  • “Atrasentan”, 12 entries
  • “Drug: Atrasentan”, 1 entry
  • “atrasentan”, 1 entry
  • “0.25 mg Atrasentan QD”, 1 entry
  • “0.75 mg Atrasentan QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.